Lucid Diagnostics Inc.LUCD
What Lucid Diagnostics Inc. does.
Unless the context otherwise requires, “ we ” , “ us ” , and “ our ” , the “ Company ” , “ Lucid ” and “ Lucid Diagnostics ” refer to Lucid Diagnostics Inc. and its subsidiaries LucidDx Labs Inc. ( “ LucidDx Labs ” ) and CapNostics, LLC ( “ CapNostics ” ).
Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics technology company. Lucid is focused on the millions of patients with gastroesophageal reflux disease (“GERD”), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (“EAC”).
We believe that our flagship product, the EsoGuard Esophageal DNA Test, performed on samples collected with the EsoCheck Esophageal Cell Collection Device, constitutes the first and only commercially available diagnostic test capable of serving as a widespread testing tool with the goal of preventing EAC deaths, through early detection of esophageal precancer in at-risk GERD patients.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $500,000 | $377,000 | $2.4M | $4.3M | $4.7M |
| Net income | -$8.3M | -$28.1M | -$56.2M | -$52.7M | -$45.5M | -$58.0M |
| Free cash flow | — | -$18.5M | -$32.9M | — | -$44.4M | -$46.7M |
More on LUCD.
- Lucid Diagnostics Inc. summary
- Lucid Diagnostics Inc. financial statements
- Lucid Diagnostics Inc. key metrics
- Lucid Diagnostics Inc. health scores and style box
- Lucid Diagnostics Inc. earnings
- Lucid Diagnostics Inc. dividends
- Lucid Diagnostics Inc. valuation
- Lucid Diagnostics Inc. ownership and insiders
- Lucid Diagnostics Inc. peers
Figures from Lucid Diagnostics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.